Biomarkers /
MET Amplification
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
MET Amplification is a predictive biomarker for use of capmatinib, crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib in patients.
Of the therapies with MET Amplification as a predictive biomarker, 7 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against MET Amplification or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended by NCCN for patients with high-level MET amplification. |
Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended by NCCN under Category 2A for patients with high-level MET amplification or MET exon 14 skipping mutations. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
MET Amplification serves as an inclusion eligibility criterion in 66 clinical trials, of which 39 are open and 27 are closed. Of the trials that contain MET Amplification as an inclusion criterion, 1 is early phase 1 (0 open), 25 are phase 1 (11 open), 8 are phase 1/phase 2 (4 open), 28 are phase 2 (22 open), 3 are phase 3 (1 open), and 1 is no phase specified (1 open).
Trials with MET Amplification in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, malignant solid tumor, adenocarcinoma of the gastroesophageal junction, gastric carcinoma, and lymphoma [5].
Crizotinib, capmatinib, savolitinib, cabozantinib, and capivasertib are the most frequent therapies in trials with MET Amplification as an inclusion criteria [5].
Significance of MET Amplification in Diseases
Non-Small Cell Lung Carcinoma +
MET Amplification is an inclusion criterion in 29 clinical trials for non-small cell lung carcinoma, of which 19 are open and 10 are closed. Of the trials that contain MET Amplification and non-small cell lung carcinoma as inclusion criteria, 10 are phase 1 (6 open), 4 are phase 1/phase 2 (3 open), 14 are phase 2 (10 open), and 1 is phase 3 (0 open) [5].
Afatinib, capmatinib, crizotinib, dacomitinib, erlotinib, gefitinib, and osimertinib have evidence of efficacy in patients with MET Amplification in non-small cell lung carcinoma [5].
Malignant Solid Tumor +
MET Amplification is an inclusion criterion in 22 clinical trials for malignant solid tumor, of which 11 are open and 11 are closed. Of the trials that contain MET Amplification and malignant solid tumor as inclusion criteria, 11 are phase 1 (3 open), 5 are phase 1/phase 2 (2 open), and 6 are phase 2 (6 open) [5].
Colorectal Carcinoma +
MET Amplification is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain MET Amplification and colorectal carcinoma as inclusion criteria, 4 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Hepatocellular Carcinoma +
MET Amplification is an inclusion criterion in 6 clinical trials for hepatocellular carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MET Amplification and hepatocellular carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
MET Amplification is an inclusion criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain MET Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [5].
Breast Carcinoma +
MET Amplification is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MET Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [5].
Cancer +
MET Amplification is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain MET Amplification and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 3 are phase 1 (2 open) [5].
Gastric Adenocarcinoma +
MET Amplification is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain MET Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [5].
Gastric Carcinoma +
MET Amplification is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MET Amplification and gastric carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (0 open) [5].
Squamous Cell Lung Carcinoma +
MET Amplification is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET Amplification and squamous cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (1 open) [5].
Bladder Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Endometrial Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].
Glioblastoma +
MET Amplification is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain MET Amplification and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].
Head And Neck Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Amplification and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].
Lymphoma +
MET Amplification is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MET Amplification and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].
Melanoma +
MET Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Multiple Myeloma +
MET Amplification is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].
Pancreatic Adenocarcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Amplification and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].
Prostate Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Renal Cell Carcinoma +
MET Amplification is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Soft Tissue Sarcoma +
MET Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MET Amplification and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Adrenal Cortex Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Alveolar Soft Part Sarcoma +
MET Amplification is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
MET Amplification is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cholangiocarcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Clear Cell Sarcoma Of Soft Tissue +
MET Amplification is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [5].
Colorectal Adenocarcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Diffuse Intrinsic Pontine Glioma +
MET Amplification is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ewing Sarcoma +
MET Amplification is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Glioma +
MET Amplification is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gliosarcoma +
MET Amplification is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Hepatoblastoma +
MET Amplification is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Lung Adenocarcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lung Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
MET Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Medulloblastoma +
MET Amplification is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Mesothelioma +
MET Amplification is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Osteosarcoma +
MET Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Papillary Renal Cell Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].
Rhabdomyosarcoma +
MET Amplification is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid Gland Medullary Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Urothelial Carcinoma +
MET Amplification is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Wilms Tumor +
MET Amplification is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET Amplification and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
